Clinical Trials on Motor Deficit in Japan

Total 60 results

Eli Lilly and Company

Completed

A Bioequivalence (BE) Study in Healthy Subjects

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Safety Study in Outpatient Japanese Children With ADHD

Attention Deficit Hyperactivity Disorder

Japan
Chiba University

Completed

Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial

Attention Deficit and Disruptive Behavior Disorders | Hyperkinesis | Attention Deficit Disorder With Hyperactivity Disease

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.

Multifocal Motor Neuropathy

Japan
Chiba University

Completed

An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity

Japan
Wafaa Mahmoud Amin

Withdrawn

Mental Practice Versus Proprioceptive Neuromuscular Facilitation on Strength of Upper Limb

Motor Activity

Saudi Arabia
Eli Lilly and Company

Completed

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Japan
Gunma PAZ College
Kanazawa University

Completed

Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity of Hemiplegics (LIPA)

Physical Activity | Hemiplegia | Motor Activity

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Janssen Pharmaceutical K.K.

Completed

A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit / Hyperactivity Disorder

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study for JNS001 in Adults With Attention-Deficit Hyperactivity Disorder

Attention-Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)

Attention Deficit Hyperactivity Disorder

Japan
University of Jazan

Completed

The Effects of Mental Practice Combined With Proprioceptive Neuromuscular Facilitation on Muscle Strength of Upper Limb and Hand Grip

Physical Activity | Motor Activity | Neuromuscu

Saudi Arabia
Eli Lilly and Company

Completed

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Korea, Republic of, Taiwan, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy

Japanese Patients With ALS

Japan
University of Jazan

Completed

Influence of Virtual Reality Games on Knee Proprioception After Anterior Cruciate Ligament Reconstruction (ACLR)

Motor Activity | Proprioceptive Disorders | Balance; Distorted

Saudi Arabia
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis

Japanese Patients With ALS

Japan
Chiba University

Completed

Open-label Clinical Trial of Lacosamide in ALS

Amyotrophic Lateral Sclerosis

Japan
Yoshino Neurology Clinic

Unknown

Efficacy and Safety of YAM80 in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Japan
Kyoto University
Pfizer; Kitasato University; Tokushima University; Tottori University

Recruiting

iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Amyotrophic Lateral Sclerosis

Japan
Wafaa Mahmoud Amin
Cairo University

Completed

The Effect of BMI on Hand Grip Force in Healthy Adults

Overweight and Obesity | Motor Activity | Hand Injuries

Saudi Arabia
argenx

Recruiting

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

United States, Italy, France, Bulgaria, Serbia, Latvia, Czechia, Poland, China, Sweden, Japan, Romania
Mitsubishi Tanabe Pharma Corporation

Completed

Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)

Japan
Takeda

Recruiting

Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

Spinal and Bulbar Muscular Atrophy

Japan
Takeda

Active, not recruiting

A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | Multifocal Motor Neuropathy (MMN)

Japan
Tokyo Medical University

Completed

Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)

ALS

Japan
AstraZeneca

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE)

Advanced Solid Tumours That Are MTAP Deficient

United States, Spain, Korea, Republic of, Australia, Japan, China, Netherlands, France
Novartis Gene Therapies
PRA Health Sciences

Completed

Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies

Spinal Muscular Atrophy Type I

Korea, Republic of, Taiwan, Japan
University of Tokushima
Eisai Co., Ltd.

Unknown

Clinical Trial of Ultra-high Dose Methylcobalamin for ALS (JETALS)

Amyotrophic Lateral Sclerosis

Japan
University Medical Center Groningen
University of Sao Paulo; Dokkyo Medical University; Somogy Megyei Kaposi Mór... and other collaborators

Unknown

Beam Walking Across the Lifespan for Falls Prediction (BEAM)

Stroke | Parkinson Disease | Cognitive Impairment | Dementia | Aging | Postural; Defect | Diagnoses Disease

Netherlands, Brazil, Germany, Hungary, Japan
Novartis Gene Therapies
PRA Health Sciences

Completed

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 (SPR1NT)

Spinal Muscular Atrophy

United States, United Kingdom, Australia, Belgium, Canada, Japan
Novartis Pharmaceuticals

Active, not recruiting

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam (STRENGTH)

Spinal Muscular Atrophy

Japan, Belgium, Spain, Canada, United States, Australia, Italy, France, Netherlands
Novartis Pharmaceuticals

Recruiting

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (SPECTRUM)

Spinal Muscular Atrophy (SMA)

Spain, Canada, Taiwan, Belgium, Japan, Italy, Singapore, United Kingdom, France, Australia, Denmark, United States
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
Hoffmann-La Roche

Recruiting

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy (MANATEE)

Spinal Muscular Atrophy (SMA)

Belgium, United States, Croatia, Japan, Netherlands, Spain, Canada, Poland, United Kingdom, Portugal, Italy, Australia
Biogen

Recruiting

A Study to Evaluate Higher Dose (HD) Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Previously Treated With Risdiplam (ASCEND)

Spinal Muscular Atrophy

United States, Germany, Italy, Hungary, Japan
Hoffmann-La Roche

Completed

Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy (FIREFISH)

Muscular Atrophy, Spinal

Belgium, United States, China, Spain, Japan, France, Brazil, Croatia, Italy, Russian Federation, Saudi Arabia, Serbia, Switzerland, Turkey, Ukraine, Poland
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Hoffmann-La Roche

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

Muscular Atrophy, Spinal

Belgium, United States, China, Spain, Japan, Canada, France, Poland, Brazil, Croatia, Italy, Russian Federation, Turkey, Germany, Serbia, United Kingdom
GlaxoSmithKline

Completed

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States, France, Australia, Canada, Belgium, Germany, Korea, Republic of, Japan, Netherlands, Italy, United Kingdom
Biogen

Enrolling by invitation

Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen (ONWARD)

Muscular Atrophy, Spinal

United States, Spain, Taiwan, Chile, Saudi Arabia, Brazil, Russian Federation, Mexico, Germany, Estonia, Japan, Canada, Colombia, Lebanon, Poland, Italy, China
Apellis Pharmaceuticals, Inc.

Terminated

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

United States, Netherlands, Spain, Germany, Japan, Australia, France, Poland, Ukraine, Belgium, Czechia, Ireland, Italy, United Kingdom
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Biogen
Ionis Pharmaceuticals, Inc.

Completed

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) (VALOR (Part C))

Amyotrophic Lateral Sclerosis

United States, Canada, Belgium, France, Australia, Japan, Denmark, Korea, Republic of, United Kingdom, Germany, Italy, Poland
PTC Therapeutics

Active, not recruiting

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS (CARDINALS)

Amyotrophic Lateral Sclerosis

United States, Belgium, Spain, Australia, Germany, Italy, Czechia, France, Netherlands, Japan, Poland, Argentina, Sweden
Sanofi

Terminated

Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)

Amyotrophic Lateral Sclerosis

Netherlands, China, Poland, Italy, Belgium, United States, Canada, France, Germany, Japan, Spain, Sweden, United Kingdom
Population Health Research Institute
The Hospital for Sick Children

Completed

Tetralogy of Fallot for Life (TOF-LIFE)

Tetralogy of Fallot | Congenital Heart Disease | Congenital Heart Defect

Canada, United States, Korea, Republic of, Australia, China, Japan, India, Indonesia, Nepal, Russian Federation, Saudi Arabia, Ukraine

Clinical Trials on Motor Deficit in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations